<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02410122</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00092688</org_study_id>
    <nct_id>NCT02410122</nct_id>
  </id_info>
  <brief_title>The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy</brief_title>
  <acronym>ProgStar-4</acronym>
  <official_title>The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4 (STGD4): A Prospective Longitudinal Observational Study of Stargardt Disease Type 4, a PROM1- Related Macular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Shulsky Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      While a fair amount of clinical data on Stargardt disease type 1 (STGD1) have been published,&#xD;
      very little is known about Stargardt disease type 4 (STGD4). The ProgStar 04 study is an&#xD;
      important opportunity to leverage the infrastructure, clinical trials sites, methods, and&#xD;
      central reading center of the ProgStar program to investigate the progression of STGD4 and&#xD;
      will help to establish patient cohorts worldwide for future clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PROM1 gene codes a protein called Prominin 1 (PROM1; also known as CD133 and AC133), most&#xD;
      known for its original use as a human stem cell-specific marker. In the retina, PROM1 is&#xD;
      involved in the formation and organization of disks within the outer segment (OS) of the&#xD;
      photoreceptors. It is within this particular region that most of the electrochemical signals&#xD;
      in response to light are generated (visual cycle-phototransduction). In STGD4, mutations in&#xD;
      the PROM1 gene result in a defective isoform of the PROM1 protein that becomes trapped in the&#xD;
      myoid region of the photoreceptors and cannot migrate to the OS site where disks are formed.&#xD;
      Ultimately, the absence of PROM1 in the OS affects the growth and organization of the disks,&#xD;
      which leads to disk malfunction and to vision problems.&#xD;
&#xD;
      Although many advances in genetic science have helped to recognize this variant of STGD, a&#xD;
      comprehensive description of the natural history, including the variability in cone and rod&#xD;
      dysfunction, of this STGD variant is not available. While there is no known treatment for&#xD;
      STGD at this time, the preparation for future therapeutic approaches and for planning&#xD;
      clinical trials must include an understanding of the disease itself, its variability, its&#xD;
      progression and its correlation with visual loss. Moreover, clinical trials that aim to slow&#xD;
      down the progression and/or to restore vision require validated outcome measures to prove&#xD;
      treatment efficacy. However, such outcomes have not been established for STGD overall.&#xD;
&#xD;
      In summary, the characterization of STGD4-specific clinical manifestations, progression and&#xD;
      prognosis as well as identification of outcome measures for clinical trials are critical to&#xD;
      develop new clinical trials for STGD4. Hence, ProgStar 4 is developed as a prospective&#xD;
      longitudinal observational study of patients with mutations in the PROM1 gene and a phenotype&#xD;
      consistent with STGD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Growth of atrophic lesions as measured by fundus autofluorescence (FAF) imaging</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Growth of atrophic lesions as measured by fundus autofluorescence (FAF) imaging</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of retinal thinning and photoreceptor loss as measured by spectral domain optical coherence tomography (sd-OCT)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of retinal thinning and photoreceptor loss as measured by spectral domain optical coherence tomography (sd-OCT)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss of retinal sensitivity as measured by microperimetry</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss of retinal sensitivity as measured by microperimetry</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in best-corrected visual acuity by using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in best-corrected visual acuity by using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of all outcome measures with genetic profile</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of all outcome measures with genetic profile</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">15</enrollment>
  <condition>Stargardt Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study shall enroll participants with PROM1 mutations and associated STGD4 phenotype at&#xD;
        up to 10 clinical sites.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide a signed informed consent form and authorization allowing the disclosure and&#xD;
             use of protected health information.&#xD;
&#xD;
          2. The designated primary study eye must have at least one well-demarcated area of&#xD;
             atrophy. The lesion size should not exceed the area to be tracked in the OCT mode&#xD;
             (20x20 degrees).&#xD;
&#xD;
          3. Have at least one pathogenic mutation confirmed in the PROM1 gene and a Stargardt&#xD;
             phenotype.&#xD;
&#xD;
          4. The primary study eye must have clear ocular media and adequate pupillary dilation to&#xD;
             permit good quality FAF and sd-OCT imaging in the opinion of the investigator.&#xD;
&#xD;
          5. Be able to cooperate in performing the examinations.&#xD;
&#xD;
          6. Be willing to undergo ocular examinations once every 6 months for up to 24 months.&#xD;
&#xD;
          7. Be at least six years old.&#xD;
&#xD;
          8. Both eyes can be included if inclusion criteria are fulfilled for both eyes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ocular disease, such as choroidal neovascularization, glaucoma and diabetic&#xD;
             retinopathy, in either eye that may confound assessment of the retina morphologically&#xD;
             and functionally.&#xD;
&#xD;
          2. Intraocular surgery in the primary study eye within 90 days prior to baseline visit.&#xD;
&#xD;
          3. Current or previous participation in an interventional study to treat STGD such as&#xD;
             gene therapy or stem cell therapy. Current participation in a drug trial or previous&#xD;
             participation in a drug trial within six months before enrollment. The use of oral&#xD;
             supplements of vitamins and minerals are permitted although the current use of Vitamin&#xD;
             A supplementation shall be documented.&#xD;
&#xD;
          4. The site Principal Investigator may declare any patient at their site ineligible to&#xD;
             participate in the study for a sound medical reason prior to the patient's enrollment&#xD;
             into the study.&#xD;
&#xD;
          5. Any systemic disease with a limited survival prognosis (e.g. cancer, severe/unstable&#xD;
             cardiovascular disease).&#xD;
&#xD;
          6. Any condition that would make adherence to the examination interfere with the patient&#xD;
             attending their regular follow-up visits schedule of once every 6 months for up to 24&#xD;
             months difficult or unlikely, e.g. personality disorder, use of major tranquilizers&#xD;
             such as Haldol or Phenothiazine, chronic alcoholism, Alzheimer's Disease or drug&#xD;
             abuse.&#xD;
&#xD;
          7. Evidence of significant uncontrolled concomitant diseases such as cardiovascular,&#xD;
             neurological, pulmonary, renal, hepatic, endocrine or gastro-intestinal disorders.&#xD;
&#xD;
          8. Patient is known to have one or more pathogenic mutation(s) in the ABCA4, RDS, or&#xD;
             ELOVL4 genes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Wilmer Eye Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Foundation of the Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit√§ts-Augenklinik Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Opthalmic Research, University of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <link>
    <url>http://progstar.org/progstar-home/progstar-4/</url>
    <description>Click here for more information about this study: the Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar)</description>
  </link>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 5, 2015</study_first_submitted>
  <study_first_submitted_qc>April 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2015</study_first_posted>
  <last_update_submitted>August 1, 2018</last_update_submitted>
  <last_update_submitted_qc>August 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stargardt Disease</mesh_term>
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

